PIONEER-AF-PCI Bleeding Algorithm Calculator
Trial strategy explorer
Enter renal function and select the trial arm to review its regimen and published bleeding result.
TRIAL SUMMARY
How to interpret the trial results
PIONEER AF-PCI enrolled patients with nonvalvular atrial fibrillation who underwent PCI with stent placement. The primary safety endpoint was clinically significant bleeding during 12 months of follow-up.
| Trial group | Bleeding | Hazard ratio vs Group 3 |
|---|---|---|
| Group 1: rivaroxaban + P2Y12 inhibitor | 16.8% | 0.59 (95% CI 0.47–0.76) |
| Group 2: rivaroxaban + DAPT strategy | 18.0% | 0.63 (95% CI 0.50–0.80) |
| Group 3: VKA + DAPT strategy | 26.7% | Reference |
Important limitations
- These percentages describe trial groups; this calculator does not estimate an individual's bleeding probability.
- The trial was not designed to establish definitive differences in ischemic efficacy between strategies; efficacy estimates had limited precision.
- Patients with CrCl below 30 mL/min were excluded, limiting applicability to severe renal impairment.
- Trial regimens should not be assumed to match currently approved doses for every indication or patient.
References
Gibson CM, Mehran R, Bode C, et al.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. N Engl J Med. 2016;375:2423–2434. DOI: 10.1056/NEJMoa1611594. PMID: 27959713.
American College of Cardiology.PIONEER AF-PCI trial summary, including treatment arms, renal exclusion criterion, and bleeding outcomes. Read trial summary.
Clinical disclaimer: Educational and reference use only. This tool summarizes trial arms and published group-level bleeding outcomes; it does not recommend a regimen for an individual patient. Treatment after PCI in atrial fibrillation requires assessment of thromboembolic and ischemic risk, bleeding risk, renal function, drug interactions, contraindications, and current guideline and regulatory recommendations. Do not use the very-low-dose rivaroxaban trial regimen as a substitute for appropriate anticoagulation for AF stroke prevention without specialist review.
PERSONAL WORKSPACE
Clinical notes
Document key findings and keep a structured record for your own reference.
Private by design. Notes are stored in this browser on this device only. They are not uploaded to Appcardio.
Export or share this note
PERSONAL WORKSPACE
My notes
Review, edit, or remove notes saved in this browser.
Stored locally on this device
QUALITY & SAFETY
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.
Please describe the issue clearly. For calculation concerns, include the input values and expected result where possible.